What are the adverse reactions of mbelantuzumab and how to deal with them?

Berantuzumab (trade name: Blenrep) is an antibody-drug conjugate (ADC) against multiple myeloma that exerts anti-tumor effects by targeting B cell maturation antigen (BCMA) and releasing the microtubule inhibitor MMAF. However, as an innovative drug, berantuzumab may cause a series of adverse reactions during treatment. Understanding these adverse reactions and how to deal with them is crucial to ensuring patient medication safety.

Common adverse reactions to berantuzumab include infusion reactions, eye problems, vision changes, abnormal laboratory test results, fever, fatigue, nausea, etc. Among them, infusion reaction is one of the common side effects of ADC drugs, which may manifest as dizziness, fatigue, nausea, itching, fever, chills, sweating, shortness of breath, rapid heartbeat, difficulty breathing, or facial swelling. In addition, belantuzumab may cause eye problems, such as vision changes, dry eyes, or vision loss, and patients should promptly report this to their ophthalmologist.

Patients and medical staff need to remain highly vigilant about the adverse reactions of berantuzumab. Seek medical attention immediately if you have any signs of a suspected allergic reaction, such as hives, difficulty breathing, swelling of the face, lips, tongue, or throat. For mild to moderate adverse reactions such as infusion reactions, patients should promptly inform the doctor, and the doctor will take corresponding measures according to the patient's specific situation, such as adjusting the infusion speed and giving anti-allergic drugs.

When dealing with the adverse reactions of belantuzumab, patients also need to pay attention to the following points: first, be sure to use the drug under the guidance of a professional doctor to ensure that it is consistent with the disease condition and follow the doctor's instructions; second, regularly monitor physical condition and laboratory indicators to detect and deal with potential adverse reactions in a timely manner; third, maintain good living habits and mentality, which can help reduce the occurrence and extent of adverse reactions.

In addition, for certain serious adverse reactions, such as sudden vision loss, easy bruising, abnormal bleeding, or signs of brain bleeding, patients should call their doctor immediately and seek emergency medical assistance. When necessary, doctors may adjust the treatment plan based on the patient's specific situation, such as delaying or permanently stopping berantuzumab treatment.

In short, as an innovative drug, berantuzumab provides a new treatment option for patients with multiple myeloma, but its adverse reactions cannot be ignored. Patients and medical staff need to fully understand these adverse reactions and their response measures to ensure safe and effective medication. At the same time, patients should also maintain a good mentality and living habits, and actively cooperate with treatment in order to obtain the best treatment effect.

Reference materials:https://www.drugs.com/search.php?searchterm=Blenrep&sources%5B%5D=professional